OPTN (OptiNose) 3-Year EBITDA Growth Rate : 81.00% (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is OptiNose 3-Year EBITDA Growth Rate?

OptiNose's EBITDA per Share for the three months ended in Dec. 2024 was $0.39.

During the past 3 years, the average EBITDA Per Share Growth Rate was 81.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 65.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of OptiNose was 81.00% per year. The lowest was -33.40% per year. And the median was 30.15% per year.

Competitive Comparison of OptiNose's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptiNose's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OptiNose's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where OptiNose's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

OptiNose 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

OptiNose (NAS:OPTN) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

OptiNose 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of OptiNose's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiNose Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Township Line Road, Suite 300, Yardley, PA, USA, 19067

Website

https://www.optinose.com

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Executives

Marino Michael F Iii	officer: Chief Legal Officer & Corp Sec	C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud	officer: President & COO	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence	officer: Chief Commercial Officer	1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick	officer: Chief Accounting Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
Peter K Miller	director, officer: Chief Executive Officer	C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc	10 percent owner	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis	officer: Acting Chief Financial Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli	officer: Chief Commercial Officer	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm	10 percent owner	30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080